Max Healthcare Expands in Pune with ₹1,020 Cr Investment for 450-Bed Hospital
Max Healthcare Institute Limited is set to expand its presence in Pune with a significant investment of ₹1,020 crore to develop a 450-bed super speciality hospital. This strategic move is part of the company's broader expansion strategy to cater to the increasing demand for quality healthcare services in the region.
The acquisition of Yerawada Properties Private Limited (YPPL), a real estate development company, will enable Max Healthcare to establish the hospital in Yerawada, a prime locality in central Pune. YPPL, originally incorporated as a Limited Liability Partnership on February 19, 2024, and later converted into a company on November 14, 2025, owns a 1.68-acre freehold land parcel in central Pune, capable of accommodating the 450-bed hospital.
The total investment of ₹1,020 crore includes the cost of share acquisition, construction, equipment, stamp duty, and registration charges. The project will be funded through a mix of internal accruals and term loans, reflecting a prudent financial strategy. The phased acquisition of Class B shares over the next four years aligns with the completion timeline for the hospital project.
Max Healthcare's existing network has a total capacity of approximately 5,200 beds as of September 30, 2025, with network hospitals operating at over 76% capacity utilisation in the first half of FY26. This highlights the strong need for additional capacity to meet the growing healthcare demand in Pune and surrounding regions.
The hospital project aims to serve Pune's growing population, particularly the middle-class segment, by providing high-quality healthcare services. The development of the 450-bed facility will enhance Max Healthcare’s capacity, improve access to advanced medical care, and strengthen the company’s competitive position in the region. The phased execution over four years ensures careful planning, cost management, and alignment with long-term strategic objectives.
Max Healthcare Institute Ltd is one of India’s leading private healthcare providers, operating a network of multi-speciality and super-speciality hospitals across the country. Established with a focus on delivering advanced medical care, the company offers comprehensive healthcare services, including tertiary and quaternary care. The company demonstrates a Return on Capital Employed (ROCE) of 14.9% and a Return on Equity (ROE) of 12.7%, with a debt-to-equity ratio of 0.33. Over the past five years, it has achieved an impressive Compound Annual Growth Rate (CAGR) of 80.5% in profit growth, reflecting strong operational and financial performance.
As of Q2FY26, the company reported strong year-on-year growth across key financial metrics. Sales rose by 25% to ₹2,135 crore compared to ₹1,707 crore in Q2FY25. EBITDA increased by 28% to ₹575 crore, up from ₹451 crore a year earlier. Net profit surged by 74% to ₹491 crore, against ₹282 crore in the same period last year, while Earnings Per Share (EPS) grew 74% to ₹5.05 from ₹2.90.
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article.
